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The major immediate-early (IE) promoter of human cytomegalovirus directs the expression of several
differentially spliced and polyadenylated mRNAs that encode isoformic proteins with apparent molecular
masses of 55, 72, and 86 kDa. All of these proteins are potent transcriptional regulatory proteins. We are
interested in the collateral interactions between human cytomegalovirus and human immunodeficiency virus
(HIV) in the context of dual infection of a cell. The roles of the specific IE protein isoforms and their respective
response elements involved in trans activation of the HIV long terminal repeat (LTR) are not known. Here we
present evidence that major IE proteins IE86, IE72, and IE55 are capable of trans-activating the HIV LTR in
a T-cell line, HUT-78. The IE55 isoform noncooperatively stimulates the HIV LTR in the presence of either
isoform IE72 or IE86. Interactions between isoforms IE72 and IE86, however, result in strong synergistic
activation of the LTR. Our results suggest that a specific 155-amino-acid protein domain that is unique for the
IE86 protein participates in this synergic interaction. Point mutational analysis of the LTR identified a distinct
cis-acting target site, located between nucleotide positions -174 and -163, that mediates exclusively synergistic
trans activation by the IE72 and IE86 proteins. Finally, this study underscores the role of a cellular
intermediate(s) for communicating the synergic interactions between two IE trans activators.
AIDS is clinically characterized by severe immunosup-
pression followed by subsequent unretarded growth of op-
portunistic infections. Manifestation of AIDS may not occur
until years after initial infection by human immunodeficiency
virus (HIV). The precise pathogenic mechanism which de-
termines the development of the disease state in HIV-
infected people is unknown. The diversity of responses to
HIV infection suggests that a number of factors contribute to
the pathogenesis of the disease. Human cytomegalovirus
(HCMV) is a critical cofactor in AIDS associated with more
rapid progression to disease (14, 32, 51). The possible
interactions between these two viruses may exist at a
number of distinct levels (reviewed in reference 32). At the
molecular level, the transcriptional regulatory proteins of
one virus may be able to influence the other. The observa-
tion that the same cell can be coinfected by HIV and HCMV
in vivo (5, 34) indicates the importance of the direct inter-
actions that may occur.
The major immediate-early (IE) gene of HCMV (11, 23,
30, 45, 49, 50, 52) expresses multiple nuclear phosphopro-
teins which act as either activators or repressors of tran-
scription, depending on the cell type and target promoter
(1-4, 8-10, 12, 13, 22, 26, 28, 29, 31, 33, 35-39, 42-44, 48).
The major IE gene of HCMV has been assigned two main
regions, 1 (IE-1/UL123) and 2 (IE-2/UL122) (7, 45-47).
Formally, the IE gene contains at least seven exons which,
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because of differentially spliced and polyadenylated
mRNAs, translate into three variant isoforms with apparent
molecular masses of 55, 72, and 86 kDa (42). In addition,
region 2 contains an internal late promoter that directs the
synthesis of an unspliced mRNA encoding an in-frame
polypeptide with part of exon 7 coding sequences and has an
apparent molecular mass of 40 kDa (42). The 72-kDa protein
(IE72) is the product from IE region 1 mRNA assembled
from exons 1, 2, 3, and 4, inclusive. In contrast, the 86
(IE86)- and 55 (IE55)-kDa variant phosphoproteins are the
products of mRNAs assembled from IE region 1 exons 1, 2,
and 3 spliced with IE region 2 sequences encompassing
exons 5 and 6 for the IE55 protein mRNA and exon 7 for the
IE86 protein-encoding mRNA, respectively (Fig. 1). Previ-
ously, we have isolated cDNA clones of the major IE gene
products encoding isoforms IE72, IE86, and IE55 (43). The
availability of cDNA clones corresponding to the various IE
proteins has greatly facilitated the identification of protein
products responsible for mediating the specific activity that
had previously been ascribed to IE regions 1 and 2. The IE72
and IE86 products were identified as positive activators of
early cytomegalovirus gene expression and demonstrated
strong synergistic activity (28, 43). The IE86 protein was
characterized as the repressor for autoregulation of the
major IE promoter (MIEP), while IE72 was shown to be an
activator of the MIEP (43). Recently, the IE55 protein has
also been shown to be a potent transcriptional activator of
the MIEP (2).
Several studies have examined the role of the major IE
gene products in trans activation of the HIV long terminal
repeat (LTR) with expression vectors based on genomic
fragments from regions 1 and 2 (1, 3, 6, 10, 31, 32, 37, 38).
However, little is known about which precise isoform is
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FIG. 1. Structure of the major IE gene of HCMV. IE-1 and IE-2
designate IE regions 1 and 2, LP represents the late promoter, and
the arrows indicate the transcription initiation sites. The letter A
marks the polyadenylation signal sequence. The exons are num-
bered and represented by boxes. The shaded areas indicate the
translated regions. Above the genomic configuration of the major IE
gene is shown the late gene transcript encoding a polypeptide with
an apparent molecular mass of 40 kDa. Below are shown the splicing
configurations for the IE transcripts for the 72-, 55-, and 86-kDa
isoforms.
responsible for the trans activation event. For example,
Davis et al. (10) demonstrated that region 2, but not region 1,
products were responsible for trans activation of the HIV
LTR. However, increased LTR activity was observed when
both region 1 and 2 products were present in the cell. To
date, HIV LTR sequences encompassing the cap site (nu-
cleotides -6 and +20) have been shown to mediate respon-
siveness to the cytomegalovirus IE proteins (3). In addition,
region 1 products have been proposed to induce NF-KB in
autoregulating the MIEP (39). Since NF-KB elements exist in
the HIV LTR, those sites may be potential targets of the IE
proteins. Therefore, we have sought to delineate the role of
the major IE gene products in activating the HIV LTR and
determine whether they act via specific target sequences.
MATERIALS AND METHODS
Recombinant plasmids. Recombinant plasmids pSVH,
pSVHml7, pSVCC3, pIE55, pIE72, and pIE86 have already
been described (43). The cDNAs for the 55-, 72-, and 86-kDa
IE proteins were cloned into a Rous sarcoma virus (RSV)
expression vector (pBlueRSV). The structures of the major
IE gene and transcript products are illustrated in Fig. 1. To
construct pBlueRSV, the 592-bp NdeI-HindIII fragment
(containing the entire RSV LTR) from pNM52 was isolated,
mung bean nuclease treated, and subcloned into the blunted
EcoRI site of pBluescriptlISK (Stratagene). For construc-
tion of the 72-kDa effector plasmid (pRSV72), the 2.2-kb
EcoRI-HindIII fragment containing the entire coding se-
quence of pIE72 was purified, and the EcoRI end was
blunted and ligated into the EcoRV and HindIII sites of
pBlueRSV. The cDNAs of the 55- and 72-kDa proteins have
exons in common with the 86-kDa cDNA (42). This was
exploited in the construction of effector plasmids pRSV55
and pRSV86. The pIE55 and pIE86 plasmids were digested
with HpaI and HindIll. The purified 1.8- and 2.5-kb frag-
ments of pIE55 and pIE86, respectively, were substituted for
the 1.7-kb HpaI-HindIlI fragment of pRSV72. The resulting
constructs, pRSV55 and pRSV86, contain the complete
coding sequences of the IE55 and IE86 proteins, respec-
tively. HIV LTR chloramphenicol acetyltransferase (CAT)
reporter plasmids and the construction of oligonucleotide-
directed mutations in the LTR have been previously de-
scribed (16-18, 20, 21, 53). These mutant constructs were
previously assayed in both DNase I footprinting assays and
transient expression assays. The mutations eliminate the
binding of their cognate cellular DNA-binding protein. For a
summary in schematic form of the HIV LTR constructs used
in this study, see Fig. 5.
Transient transfections and CAT assays. Suspension cul-
tures of HUT-78 cells were maintained in RPMI medium
with 7% fetal calf serum; 1% each penicillin, streptomycin,
amphotericin B; and 1.2% glutamine. Approximately 2 x 107
cells per 500-,I aliquot were incubated on ice for 20 min with
effector and reporter DNAs, as specified in the figure leg-
ends. Electroporations were performed with a Bio-Rad Gene
Pulser at a capacitance of 960 ,uF and 250 mV in a 0.4-cm
electrode gap sterile gene pulser cuvette (Bio-Rad). Samples
were further incubated on ice for an additional 15 min and
subsequently plated on 60-mm-diameter tissue culture dishes
with 3 ml of RPMI medium. After 24 h, the transfected cells
were harvested and lysates were prepared by the freeze-
thaw method. CAT enzymatic assays were performed as
previously described (19) and quantitated by scintillation
counting.
RESULTS
trans activation of the HIV LTR by specific IE isoforms. To
determine whether IE isoforms IE86, IE72, and IE55 can
potentially activate the HIV LTR, cDNA expression vectors
encoding the respective isoforms under the control of the
RSV LTR were cotransfected in a dose-response manner
with the HIV LTR (-453 to +80) (WT943) linked to the CAT
reporter gene. Increasing amounts of pRSV without the IE
cDNAs did not influence the level of expression of the HIV
LTR (data not shown). In contrast, increasing amounts of
RSV86, RSV72, and RSV55 cotransfected with plasmid
pLTR3CAT-453 (WT943) resulted in increasing levels of
expression from the HIV LTR (Fig. 2A). The levels of
stimulation observed were approximately 22-, 36-, and 5-fold
for pRSV86, pRSV72, and pRSV55, respectively (Fig. 2B).
These results suggest that all three isoforms examined are
capable of trans activating the HIV LTR in the HUT-78
T-cell line. Significantly, the IE86 and IE72 isoforms repre-
sent strong activators of the HIV LTR while IE55 stimulates
expression to a lesser degree.
The IE72 isoform is an activator of HIV LTR activity.
Numerous investigators have shown that genomic expres-
sion vectors of IE region 2 of the major IE gene that code for
proteins IE55 and IE86 can potently activate the HIV LTR
(1, 10, 32, 38). Thus, it was not unexpected when IE86 and
IE55 were found to trans activate the HIV LTR. What was
surprising, however, was that IE72 was also found to trans
activate this promoter. Therefore, the role of IE72 in acti-
vating the HIV LTR was investigated further. Since previ-
ous investigators have used exclusively genomic expression
constructs for the MIEPs, the ability of the genomic IE
region 1 expression vector (pSVCC3) (Fig. 3A), as well as
the IE72 cDNA under control of the MIEP (pIE72) (Fig. 3A)
and the RSV LTR (pRSV72) (Fig. 3A), to trans activate the
HIV LTR was examined. Figure 3B shows that the genomic
and cDNA expression vectors trans activated pLTR3CAT-
453 to the same extent. To confirm that the observed trans
activation resulted from IE72 activity in the context of the
complete genomic region of the major IE gene, an IE region
1 mutant containing a four-amino-acid insertion at residue
position 325 (Fig. 4) was tested. This mutant, pSVHml7, has
been previously shown to eliminate IE72 activity completely
(43). In comparison with that caused by wild-type expression
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FIG. 2. Dose-response and dual-cotransfection experiments with
effector plasmids pRSV86, pRSV72, and pRSV55 and the HIV LTR
reporter (WT943). (A) Autoradiographic plate of CAT assays with
quantitations shown below the lanes. Lanes 1 to 13 were electropo-
rated with 5 jig of reporter WT943. Lanes: 1, no effector; 2 to 4, 5 to
7, and 8 to 10, cotransfections with increasing amounts of the
effectors pRSV86, pRSV72, and pRSV55, respectively; 2, 5, and 8,
cotransfections with 5,ug of each of the respective effector plasmids;
3, 6, and 9, cotransfections with 10 ,ug of the effector plasmids; 4, 7,
and 10, cotransfections with 20 ,ug of the effector plasmids. Dual
cotransfections are shown in lanes 11 to 13. Lanes: 11, 10 p.g each of
pRSV86 and pRSV72; 12, 10,ug each of pRSV86 and pRSV55; 13, 10
jig each of pRSV72 and pRSV55. (B) Summary of fold trans
activation of the HIV LTR by the IE isoformic cDNA expression
vectors individually and in combination.
vector pSVH, the level of stimulation of the HIV LTR by
pSVHml7 was severely diminished (Fig. 4). Reduced stim-
ulatory activity was also observed for mutations in the IE
region 2 coding sequences (data not shown). Importantly,
the four-amino-acid insertion mutant (pSVHml7) that re-
sides exclusively in the IE72 coding sequences abrogates
trans activation. Thus, we conclude that the IE72 protein is
important for activation of the HIV LTR by IE region 1
sequences.
Synergistic and noncooperative interactions between IE
isoforms. To assess whether the various isoforms are capable
of interacting in either a cooperative or a noncooperative
manner, dual-cotransfection experiments were performed.
Dual-cotransfection experiments with pRSV72 and pRSV55,
together with the reporter pLTR3CAT-453, resulted in an
approximately 23-fold additive stimulation effect (Fig. 2).
We interpret this effect as being additive, since the combi-
nation of IE72 and IE55 resulted in activation of the HIV
LTR that approximated the sum of the activation potentials
of the individual proteins. A similar additive activation
response (approximately 10-fold) was also observed in dual-
cotransfection experiments involving pRSV86 and pRSV55
(Fig. 2). However, examination of the response produced by
cotransfection of the pRSV72 and pRSV86 effectors with
pLTR3CAT-453 demonstrated strong (approximately 100-
fold) stimulation of the HIV LTR that significantly exceeded
the sum of the individual activation potentials (Fig. 2). We
take these results to mean that the IE72 and IE86 activators
work synergistically (cooperatively). Thus, IE55 noncooper-
atively activates the HIV promoter in conjunction with IE72
and IE86. In contrast, the IE86 and IE72 proteins together
synergistically stimulate the HIV LTR.
Mutational analysis of the HIV LTR and trans activation by
IE proteins. To determine whether a specific cis-responsive
element mediates trans activation by the IE72 and IE86
proteins, point mutations throughout the LTR were intro-
duced and examined for the ability to be trans activated.
These mutations were directed to sites of known protein-
DNA interactions defined by DNase I footprinting studies
and have previously been shown to abolish the binding of
their respective factors (16-18, 20, 21, 53). Schematics of the
deletion and point mutations analyzed in this study for
responsiveness and synergistic stimulation by the IE72 and
IE86 trans activators are shown in Fig. 5. The mutant HIV
LTR templates (listed in Fig. 5) were analyzed for the ability
to be trans activated by IE72 and IE86 independently (Fig.
6). Cotransfection of either pRSV72 or pRSV86 with the
mutant LTR-reporter constructs demonstrated that all were
responsive to trans activation by the individual proteins
(Fig. 6). In some cases, such as the TATA box mutation
(NTATA) and those mutations in the NF-KB binding site
(NENHB), LTR mutants were weakly activated relative to
the wild type (Fig. 7). However, since the mutations have a
dramatic effect on the basal level of expression, in particular
the mutant NTATA, the possibility that these mutant con-
structs are still fully responsive to the IE proteins cannot be
ruled out. It is not possible to distinguish between the
mutations that affect the ability of the promoter to be trans
activated and those effects that are manifested simply be-
cause the promoter has been severely compromised. For this
reason, the responsivenesses of the NTATA and NENHB
mutations were scored as ± and +, respectively (Fig. 5). We
infer from these results that the known sites of protein-DNA
interaction are not responsible for mediating the independent
mode of trans activation by IE72 and IE86. Alternatively,
multiple targets may be involved by which the mutation of
one is compensated for by a different target site.
To determine whether a specific target site communicates
the synergistic mode of trans activation of the LTR, the
promoter mutants were analyzed by dual-cotransfection
experiments. Promoter mutant NREP, which was found to
be responsive to trans activation by IE72 and IE86 indepen-
dently, abolished the ability of the HIV LTR to be synergis-
tically trans activated by those IE proteins (Fig. 5 to 7). In
contrast, synergistic trans activation was observed for mu-
tant LTR templates NABS, NENHB, 748, NENHO2,
SPlALL, NTARP, NTATA, NPOLT, NCAP, NSENSE,
and NUBP (Fig. 6 and 7). The observation that the NREP
mutant was unable to be synergistically trans activated by
IE72 and IE86 without affecting the degree to which those
individual proteins activate the LTR suggests that the two
modes of trans activation, the synergistic and independent
modes, are distinct. Promoter mutant NREP introduces
-i
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FIG. 3. IE72 trans activation of the HIV LTR. (A) Schematic representation of the expression vectors based on the genomic fragment for
IE72 (pSVCC3) and the cDNA expression vectors for the IE72 isoform under the control of the MIEP, pIE72, and the RSV LTR, pRSV72,
respectively. (B) Autoradiogram of CAT assays from dose-response cotransfection experiments with 5 ,ug of WT943 and increasing amounts
of pSVCC3, pIE72, and pRSV72. Lanes: 1, no effector plasmids; 2, 3, and 4, 5, 10, and 20 ,ug of pSVCC3, respectively; 5, 6, and 7, 5, 10,
and 20 ,ug of pIE72, respectively; 8, 9, and 10, 5, 10, and 20 jig of pRSV72, respectively.
eight nucleotide changes in the HIV LTR between nucleo-
tide positions -174 and -163 (Fig. 5). These mutations
prevent the binding of a cellular factor, most likely USF, to
the HIV LTR (17; unpublished data). Thus, we conclude that
sequences between -174 and -163 of the HIV LTR which
interact with a host-encoded DNA-binding protein mediate
synergistic trans activation by proteins IE72 and IE86.
DISCUSSION
In this study, we demonstrated that multiple IE proteins
(IE86, IE72, and IE55), encoded by both regions 1 and 2 of
the major IE gene of HCMV, cooperatively and noncooper-
atively trans activate the HIV LTR in T-cell line HUT-78.
Importantly, this study illustrates the possible role of a
cellular factor(s) in mediating synergistic activation of the
LTR by proteins IE72 and IE86.
The results of experiments that used cDNA expression
constructs to examine the roles of the IE proteins in activat-
A. B.
ing the HIV LTR independently showed that IE72 can trans
activate the LTR in addition to IE86 and IE55. Previous
studies have indicated that the region 1 IE72 protein is not
sufficient in activating the HIV LTR (10).This was based on
the results of cotransfection experiments in HeLa cells that
used genomic expression vectors of the HCMV major IE
gene. These seemingly contradictory results may be due to
the use of different expression vectors. However, constructs
were not a factor in this case, as both genomic fragments
containing only IE72 coding sequences and IE72 cDNA
expression vectors under the control of different promoters
stimulated the HIV LTR to the same extent in dose-response
experiments. Furthermore, a four-amino-acid insertion mu-
tant (exclusive for the IE72 coding sequences) in the context
of the complete IE region 1 and 2 genomic fragment abro-
gated the level of trans activation. From these data, it is
apparent that the IE72 protein has the ability to activate the
HIV LTR independently of proteins IE55 and IE86. In
agreement, recent studies by a number of different investi-
L. A. R . I . R. A. K
CTG.G[CG.CGG.ATC.CGC.G]CC.AAG.
pSVHm 17
'N
FIG. 4. trans activation of the HIV LTR by insertion mutant pSVHml7. (A) Cotransfection of WT943 with 10 ,ug of pSVH and mutant
pSVHml7, respectively. (B) Four-amino-acid insertion (in brackets) at amino acid residue 325 of the IE72 reading frame in mutant pSVHml7.
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FIG. 5. Schematic representation of the HIV LTR point mutants
examined for the ability to be trans activated by isoforms IE72 and
IE86. The full-length LTR is shown on the top (WT943), and the
locations of the enhancer, TATA box, and TAR domain are shown
by white boxes. The arrow marks the point of transcription initiation
(+ 1). Signed numbers refer to nucleotide positions relative to the
transcription initiation site. Black boxes indicate the positions of the
point mutations, and the site-specific changes are shown above the
wild-type sequence. A summary of the responsiveness and syner-
gistic trans activation by IE72 and IE86 is shown to the right of the
respective clones.
gators have also shown that genomic IE region 1 expression
vectors have the potential to stimulate the HIV LTR inde-
pendently (36, 39a). It has been proposed that trans activa-
tion of MIEP in human foreskin fibroblast cells by IE72 is
mediated by induction of cellular transcription factor NF-KB
(39). Furthermore, the extent to which the HIV LTR is trans
activated by IE region 1 and 2 proteins has been shown to be
cell type dependent (4). These observations, together with
this study, imply that the mode of action of the IE proteins
is dependent on the cellular environment. That is, their
effects are most likely manifested via cellular intermediates.
Therefore, a plausible explanation for these apparently con-
flicting observations regarding IE72 trans activation of the
HIV LTR is that such cellular intermediates are cell re-
stricted.
The mutational analysis of the HIV LTR performed in this
study did not reveal target sites for the independent mode of
trans activation by the IE proteins. A number of investiga-
tors have attempted to define the target site for trans
activation of the HIV LTR by HCMV IE proteins (1, 3, 6,
29, 31, 38). Consistent with our findings, many of these
studies also failed to detect a specific response element (1, 6,
NSENSE NUBP
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FIG. 6. CAT assays of cotransfection and dual-cotransfection
experiments with no trans activator (C) and with effector plasmids
RSV72 (72) and pRSV86 (86) with the indicated mutant HIV LTR
reporters.
29, 31, 38). However, Barry et al. (3) have shown that a
region between -6 and +20 is essential for trans activation
by an IE region 1 and 2 genomic expression vector. Although
point mutations throughout this region were examined, we
did not analyze the exact mutations used in those studies.
Furthermore, the suggestion that NF-KB is required for trans
activation of the MIEP by IE72 (39) implicates the NF-KB
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FIG. 7. Summary of fold trans activation of the mutant HIV
LTR templates from cotransfection experiments with pRSV72 (72)
and pRSV86 (86) and dual-cotransfection experiments with pRSV72
and pRSV86 (72/86).
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binding sites of the HIV LTR as a potential target. Point
mutations that prevent binding of NF-KB to the HIV LTR
(18) were still responsive to trans activation by IE72 and
IE86. The level of stimulation was reduced; however, since
these mutations may affect basal promoter functions, the
possibility that these mutant constructs are still fully respon-
sive to the IE proteins cannot be ruled out. A similar
explanation may be given for the TATA box mutant, al-
though it is likely that the ultimate effects of the IE proteins
are manifested at this region. In light of the promoter and cell
type dependence of IE protein function, the resolution of the
target sites for the independent mode of activation of the
LTR must remain an open question.
An important issue raised in this study is whether the
different IE isoforms interact in the regulation of promoters.
Here we show that isoform IE55 noncooperatively interacts
with the IE72 and IE86 proteins in stimulating the HIV LTR.
In contrast, the IE72 and IE86 proteins synergistically
interact in activation of the LTR. While this work was being
submitted for publication, a report on the activation of the
HIV LTR by genomic (IE region 1 and 2) expression vectors
in fibroblast cells, in agreement with our findings, implicated
possible synergism between products derived from IE re-
gions 1 and 2 (6). However, since those investigators used
genomic expression vectors, it was not clear which protein
products were responsible for the observed augmented ac-
tivity of the HIV LTR.
The IE55 protein is an isoform variant of the IE86 protein
that differs by a 155-amino-acid deletion between amino acid
residues 365 and 519 of IE86. This deletion arises from an
in-frame splicing event in IE region 2 (Fig. 1) (42, 43). The
finding that IE55 does not functionally synergize with IE72
implies that the specific domain unique to IE86 (i.e., residues
365 to 519) is involved in the synergic response. Thus, it is
likely that the IE72-IE86 synergism involves protein-protein
interactions that are mediated through this domain. This
protein domain contains a putative zinc finger adjacent to a
leucine-rich region (33, 43) and may mediate protein-protein
interactions by either coordination with Zn2+ (15) or hydro-
phobic contacts via the leucine-rich region (25).
Mutational analysis showed that a discrete sequence ele-
ment located between -174 and -163 in the HIV LTR is
required for IE86-IE72 synergistic activation. This sequence
element is a target site for the interaction of a host-encoded
nuclear protein (17). Point mutations that abolish the ability
of this factor to interact with the HIV LTR ablate the
synergistic trans activation by IE86 and IE72 without af-
fecting the ability of the promoter to be trans activated by
the proteins individually. Thus, these experiments provide
evidence that the independent and synergistic modes of
trans activation are distinct. UV cross-linking experiments
have identified a 50-kDa polypeptide that interacts with this
sequence domain (40) and suggested that it is transcription
factor USF-MLTF (27). Although the precise identity of this
cellular factor is not known, the data presented suggest that
a cellular intermediate, such as USF, communicates the
synergistic action of IE72 and IE86. Direct biochemical and
genetic evidence for a physical interaction between this
factor and the IE isoforms has yet to be provided. However,
the data certainly do not preclude a direct involvement for
functional synergism.
Clearly, the ability of the USF-binding site to mediate
IE86-IE72 synergism may play an important role in the
HCMV life cycle. For example, early promoters of HCMV
appear to be highly dependent on synergistic activation by
IE72 and IE86 (12, 28, 43). At least one cytomegalovirus
early promoter, the 2.7-kb early RNA promoter, has been
shown to contain a USF-binding site that is critical for
regulated expression (24, 41). In this case, we predict that
the USF-binding site in the early promoter would be respon-
sible for mediating synergistic activation by IE72 and IE86.
Thus, it is unlikely that the HIV LTR has had selective
pressure to maintain a USF-binding site simply for the
benefit of cross-trans activation by HCMV IE proteins. The
role of the USF site in the HIV life cycle has yet to be
established.
In conclusion, we have demonstrated that major IE iso-
forms IE72, IE86, and IE55 can independently trans activate
the HIV LTR. IE55 noncooperatively stimulates the HIV
LTR in the presence of isoforms IE72 and IE86. In contrast,
the IE72 and IE86 proteins interact in a manner that syner-
gistically stimulates the LTR. The synergic interactions
between IE72 and IE86 are mediated by a sequence element
(at nucleotide positions -174 to -163) that interacts with a
host-encoded DNA-binding protein. The precise identity of
this third target protein and the question of whether or not it
complexes with the IE isoforms remain to be explored.
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